Since myeloma tumors as well as many other B-cell neoplasms use NFkB to achieve survival, proliferation and resistance to anticancer drugs, inhibition of NFkB activation appears to be a very promising option for anti-cancer therapies. This evidence concerns the gene NFKB1 and cancer.